NUDT8 Inhibitors
NUDT8 inhibitors encompass a diverse group of chemical compounds that interfere with various signaling pathways and biological processes to indirectly attenuate the functional activity of NUDT8. LY294002 and Wortmannin are two such inhibitors that target the phosphoinositide 3-kinases (PI3K), thereby hindering the PI3K/AKT signaling cascade, which is integral to cellular survival and metabolism. The inhibition of this pathway by LY294002 and Wortmannin could lead to the inactivation of NUDT8 if it is regulated by or associated with AKT-mediated phosphorylation. Similarly, Rapamycin, an mTOR inhibitor, disrupts the mTORC1 signaling complex, which could result in the downregulation of NUDT8's activity if it is associated with mTORC1 pathway outputs like protein synthesis or cellular proliferation signals.
Staurosporine, a broad-spectrum kinase inhibitor, may reduce the phosphorylation and subsequent activity of NUDT8 by targeting protein kinases responsible for NUDT8 activation. 2-Deoxy-D-glucose, a glycolysis inhibitor, could decrease the energy supply necessary for NUDT8's activity, assuming NUDT8's function is energy-dependent. PD98059 and U0126, both MEK inhibitors, would lead to a reduction in ERK activation, which, in turn, could suppress the functional activity of NUDT8 if it is dependent on the MAPK/ERK pathway. SB203580, PP2, and SP600125, which inhibit p38 MAPK, Src family tyrosine kinases, and JNK respectively, could downregulate NUDT8 if its activity is modulated by stress-activated signals or if it is a downstream target of Src kinase signaling or JNK-mediated processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the activation of AKT signaling pathway, which is implicated in cellular survival and metabolism. If NUDT8 is an AKT substrate or is regulated by AKT-mediated phosphorylation, LY294002 would result in reduced activity of NUDT8 by preventing its phosphorylation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin irreversibly inhibits PI3K, leading to the inhibition of the PI3K/AKT pathway. Since this pathway is crucial for numerous cellular processes, the inhibition by Wortmannin can decrease the activity of downstream proteins such as NUDT8 if they are dependent on PI3K/AKT for activation or stabilization. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTORC1 signaling complex, leading to reduced protein synthesis and cell proliferation. If NUDT8 function is linked to mTORC1 pathway outputs, such as protein translation or cell growth signals, Rapamycin can indirectly inhibit NUDT8's functional activity by disrupting these signals. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor with broad specificity. It can inhibit protein kinases that may be responsible for the phosphorylation and activation of NUDT8. Inhibition of these kinases would lead to reduced phosphorylation and activation of NUDT8, thereby decreasing its functional activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose acts as a glycolysis inhibitor by mimicking glucose and competitively inhibiting hexokinase. If NUDT8 activity is energy-dependent or linked to metabolic signaling pathways that are fueled by glycolysis, this compound would lead to decreased energy production and thereby inhibit NUDT8 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK by PD98059 would lead to decreased ERK activation. If NUDT8 is regulated by the MAPK/ERK pathway or requires ERK-mediated phosphorylation for its activity, this inhibition would result in decreased functional activity of NUDT8. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway responds to stress signals and is involved in cell differentiation and apoptosis. Inhibition of p38 MAPK by SB203580 would result in decreased activation of downstream targets, potentially including NUDT8 if its activity is modulated by stress-activated signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the stress-activated MAPK pathway. JNK influences cell proliferation, apoptosis, and inflammation. If NUDT8 is regulated by or in association with JNK signaling, inhibition by SP600125 would reduce the functional activity of NUDT8. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases are involved in numerous signaling pathways including cell growth and differentiation. If NUDT8 is a downstream target of Src kinase signaling or requires Src kinase activity for its function, PP2 would inhibit NUDT8 activity by inhibiting Src kinases. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the MAPK/ERK pathway. If the activity of NUDT8 is dependent on signals from the ERK pathway or if NUDT8 requires ERK-mediated phosphorylation for its activity, U0126 would lead to decreased activation and functional activity of NUDT8. | ||||||